Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

rrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, the Novartis Group offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. The Novartis Group is the only company with leading positions in each of these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.us.novartis.com.

* Known as Glivec® (imatinib) outside the US, Canada and Israel.

References

(1) Ghobrial, et al. A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia. 51st American Society of Hematology Annual Meeting and Exposition, New Orleans, LA. December 5-8, 2009.

(2) Younes, et al. Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant. 51st Ameri
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Calif. , May 20, 2013 /PRNewswire-iReach/ -- ... of the first study demonstrating detection of pathogenic ... Yersinia pestis and Bacillus anthracis ... and Prevention,s list of potential bio-threats. This seminal ... and Technology Laboratory, Salisbury ...
(Date:5/20/2013)...  TRACE International today released its Global Enforcement ... against individuals and government or business entities for bribery ... 2012 is the third in an annual series ... "Although the number of outbound enforcement actions fell ... priority," said Alexandra Wrage , TRACE ...
(Date:5/20/2013)... EL SEGUNDO, Calif. , May 20, 2013 /PRNewswire/ ... helped perfect for use both in space and on ... of Fame. The technology assures high ... by compact and low-power ultrasound units, like those used ... ultrasound is already the diagnostic imaging solution of choice ...
Breaking Medicine Technology:Specific Technologies Detects and Identifies Potential Bioterrorism Pathogenic Bacteria 2TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today reported ... effects on pulmonary artery pressure of LEVADEX™, dihydroergotamine mesylate ... there was no statistically significant difference between the LEVADEX ... artery pressure over two hours after administration. LEVADEX is ...
... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader ... company overview at Stifel Nicolaus, 2010 Healthcare Conference on Thursday, ... Seasons Hotel in Boston, MA. A live audio ... & Media" section of the Company,s Web site, www.isispharm.com ...
Cached Medicine Technology:MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial 2MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial 3MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial 4
(Date:5/20/2013)... 2013 For the third consecutive ... of Frederick Award in the Professional Standards Review ... , The USCA "Best of Local Business" Award ... Each year, the USCA identifies companies that they ... local community and business category. These are local ...
(Date:5/20/2013)... The new healthcare bill proposes to ... all Americans. However, not all the conditions were to ... might take up to 2014 to show anything. ... states are currently moving forward to implement the health ... Iowa, Michigan, New Hampshire, and West Virginia. HHS will ...
(Date:5/20/2013)... Daily Gossip, online magazine about lifestyle, health and sports ... that can help them overcome one of the most spread ... Natural Vitiligo Treatment System has created a buzz on ... received from the persons who have tried it. Its principles ... interviewed some of the people who tried it and managed ...
(Date:5/20/2013)... People are so busy these days, running ... through the roof and are contributing to a number of ... mean the difference between life and death. Speakers at the ... May will share valuable, practical tools people can use to ... around them for social good. , Organised by V ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 ... Foundation will be holding a ... Lansing on June 10th. , ... 10th, 6:30 p.m. – 8 ... (Across from Sparrow Hospital),                  ...
Breaking Medicine News(10 mins):Health News:A2LA Receives 2013 Best of Frederick Award 2Health News:Review of Health Bill Impact in 2014 2Health News:Review of Health Bill Impact in 2014 3Health News:New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine 2Health News:Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney 2
... ... system that automatically matches the right clients with the right lenders making the whole ... conversions for retailers. , ... Orlando, FL (PRWEB) June 17, 2009 -- The world of Equipment Leasing/Financing is ...
... ORANGE COUNTY, Calif., June 17 Applied Medical, a ... in the Premier healthcare alliance ,s ... in healthcare while highlighting healthcare industry suppliers committed to ... Innovation Celebration highlights innovative solutions that bring a positive ...
... rescue manager won contest to clone beloved pet Trakr, hero of ... Can you clone a hero? Retired ... dog and 9-11 hero, Trakr, will receive five answers to that ... biotech company that is offering the first commercial dog cloning service ...
... Focus on promoting ... ... signed a Memorandum of Understanding (MOU) to promote healthcare travel in the Pacific Asia region. ... and drive more integration between the travel and healthcare industries., , , , ,Under the ...
... Dr. Bryan Selkin, the ... new state of the art location at 5044 Tennyson in Plano. Dr. Bryan Selkin will ... ... Selkin, the Chief Dermatologist of the Dermatology Center of Plano will be relocating his practice to ...
... Withdraws Two Cold Remedy Nasal Products Citing Commitment to Consumer ... Matrixx Initiatives, Inc. (Nasdaq: MTXX ) has ... U.S. Food and Drug Administration about two of its 19 ... Zicam Cold Remedy Swabs. The warning letter cited consumer reports ...
Cached Medicine News:Health News:The Equipment Leasing/Financing World Now Has its First Exclusive Online Referral Service 2Health News:The Equipment Leasing/Financing World Now Has its First Exclusive Online Referral Service 3Health News:Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement, Innovation 2Health News:Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement, Innovation 3Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 2Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 3Health News:The International Medical Travel Association (IMTA) and Pacific Asia Travel Association (PATA) sign MOU to Promote Healthcare Travel 2Health News:The International Medical Travel Association (IMTA) and Pacific Asia Travel Association (PATA) sign MOU to Promote Healthcare Travel 3Health News:New State of the Art Dermatology Center in Plano TX 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 3
Inquire...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
... provides an ideal treatment for ... such as the great and ... wavelength targets water in the ... means a much more comfortable ...
...
Medicine Products: